| Literature DB >> 33273210 |
Sean S Brummel1, Taha E Taha2, Konstantia Nadia Angelidou1, Friday Saidi3, Patience Atuhaire4, Dingase Dula5, Dhayendre Moodley6, Allen Matubu7, Gift Chareka7, Neetal Nevrekar8, Tichaona Vhembo9, Lee Fairlie10, Gerhard Theron11, Pendo Mlay12, Kathleen George13, Michael Basar14, Nahida Chakhtoura15, Renee Browning16, Mary Glenn Fowler17, Judith S Currier18.
Abstract
ABSTRACT: IMPAACT PROMISE 1077BF/FF was a sequentially randomized study of pregnant and postpartum women living with HIV to investigate the efficacy and safety of antiretroviral therapy (ART). This Maternal Health Component investigated efficacy for the risk of developing AIDS or death; and safety among women randomized to continue ART (CTART: N = 289) or discontinue ART (N = 268) after cessation of breastfeeding or after confirmation of infant infection. No AIDS-defining illnesses were reported during follow-up in either arm. Adverse events of grade 3 or higher were more frequent in the CTART arm [hazard ratio = 1.78, 95% confidence interval: (1.05 to 3.02), P-value = 0.03]. The difference in adverse events in the 2 groups was mostly driven by moderate weight loss for women on the CTART arm.Entities:
Mesh：
Substances：
Year: 2021 PMID： 33273210 PMCID： PMC8143379 DOI： 10.1097/QAI.0000000000002586
Source DB: PubMed Journal: J Acquir Immune Defic Syndr ISSN： 1525-4135 Impact factor: 3.771